US provides Ebola treatment for outbreak in Congo, bringing trials closer
The U.S. government is providing experimental antibody treatments to the Democratic Republic of Congo to assist in clinical trials for a widening Ebola outbreak. This marks a shift in U.S. policy, which previously restricted the drug's availability to American citizens.
Why it matters
Direct support for clinical trials in the outbreak region is a critical step in addressing the Bundibugyo strain of Ebola, for which no approved treatments currently exist.
Listen June 23 - The U.S. has provided doses of an experimental antibody drug from Mapp Biopharmaceutical for use in clinical trials to fight the widening Ebola outbreak in Democratic Republic of Congo, a Health Department spokesperson said, a shift from its position of making the drug available just for Americans.
The report objectively details the policy shift and the medical context of the outbreak.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in